Fig. 5: ADCT-701 elicits complete, durable responses in DLK1+ small cell lung cancer tumors without ABCB1 expression. | Nature Communications

Fig. 5: ADCT-701 elicits complete, durable responses in DLK1+ small cell lung cancer tumors without ABCB1 expression.

From: Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma

Fig. 5

A Cell surface DLK1 expression by flow cytometry in 3 small cell lung cancer (SCLC) cell lines (H524, H146, and H1436) (data representative of n = 3 independent experiments). B DLK1 molecules/cell relative to DLL3 among SCLC cell lines (n = 3 independent experiments). Error bars represent mean values ± S.E.M. C Flow cytometry histograms assessing ABCB1 in SCLC cell lines (data representative of n = 3 independent experiments). D SG3199 cytotoxicity in SCLC cell lines. Cells were treated with SG3199 for 3 days (data representative of n = 4 independent experiments). E ADCT-701 cytotoxicity among SCLC cell lines. Cells were treated with ADCT-701 or B12-PL1601 for 7 days (data representative of n = 4 independent experiments). F Tumor growth curves of SCLC xenograft models after treatment (1 mg/kg) with saline (H524: n = 5; H146: n = 5; H1436: n = 6), B12-PL1601 (H524: n = 5; H146: n = 4; H1436: n = 7) or ADCT-701 (H524: n = 4; H146: n = 6; H1436: n = 7) when tumor size reached an average of 100–150 mm3. Arrows indicate re-treatment with ADCT-701. Scale bars represent 200 μm. Error bars represent mean values ± S.E.M. Source data are provided as a Source Data file.

Back to article page